Literature DB >> 33006109

Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers.

Morna J Dorsey1, Nicola A M Wright2, Natalia S Chaimowitz3, Blachy J Dávila Saldaña4,5, Holly Miller6, Michael D Keller7, Monica S Thakar8, Ami J Shah9, Rolla Abu-Arja10, Jeffrey Andolina11, Victor Aquino12, J L Barnum13, Jeffrey J Bednarski14, Monica Bhatia15, Francisco A Bonilla16, Manish J Butte17, Nancy J Bunin18, Sharat Chandra19,20, Sonali Chaudhury21, Karin Chen22, Hey Chong13, Geoffrey D E Cuvelier23, Jignesh Dalal24, Magee L DeFelice25, Kenneth B DeSantes26, Lisa R Forbes27, Alfred Gillio28, Fred Goldman29, Avni Y Joshi30, Neena Kapoor31, Alan P Knutsen32, Lisa Kobrynski33, Jay A Lieberman34, Jennifer W Leiding35,36, Benjamin Oshrine36, Kiran P Patel37, Susan Prockop38, Troy C Quigg39, Ralph Quinones40, Kirk R Schultz41, Christine Seroogy42, David Shyr43,44, Subhadra Siegel45, Angela R Smith46, Troy R Torgerson8, Mark T Vander Lugt47, Lolie C Yu48, Morton J Cowan1, Rebecca H Buckley49, Christopher C Dvorak1, Linda M Griffith50, Elie Haddad51, Donald B Kohn52, Brent Logan53, Luigi D Notarangelo54, Sung-Yun Pai55,56, Jennifer Puck1, Michael A Pulsipher31, Jennifer Heimall57.   

Abstract

PURPOSE: The Primary Immune Deficiency Treatment Consortium (PIDTC) enrolled children with severe combined immunodeficiency (SCID) in a prospective natural history study of hematopoietic stem cell transplant (HSCT) outcomes over the last decade. Despite newborn screening (NBS) for SCID, infections occurred prior to HSCT. This study's objectives were to define the types and timing of infection prior to HSCT in patients diagnosed via NBS or by family history (FH) and to understand the breadth of strategies employed at PIDTC centers for infection prevention.
METHODS: We analyzed retrospective data on infections and pre-transplant management in patients with SCID diagnosed by NBS and/or FH and treated with HSCT between 2010 and 2014. PIDTC centers were surveyed in 2018 to understand their practices and protocols for pre-HSCT management.
RESULTS: Infections were more common in patients diagnosed via NBS (55%) versus those diagnosed via FH (19%) (p = 0.012). Outpatient versus inpatient management did not impact infections (47% vs 35%, respectively; p = 0.423). There was no consensus among PIDTC survey respondents as to the best setting (inpatient vs outpatient) for pre-HSCT management. While isolation practices varied, immunoglobulin replacement and antimicrobial prophylaxis were more uniformly implemented.
CONCLUSION: Infants with SCID diagnosed due to FH had lower rates of infection and proceeded to HSCT more quickly than did those diagnosed via NBS. Pre-HSCT management practices were highly variable between centers, although uses of prophylaxis and immunoglobulin support were more consistent. This study demonstrates a critical need for development of evidence-based guidelines for the pre-HSCT management of infants with SCID following an abnormal NBS. TRIAL REGISTRATION: NCT01186913.

Entities:  

Keywords:  Infections; hematopoietic stem cell transplant; newborn screening; primary immunodeficiency; prophylaxis; severe combined immunodeficiency

Mesh:

Year:  2020        PMID: 33006109      PMCID: PMC8388237          DOI: 10.1007/s10875-020-00865-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  22 in total

1.  Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening.

Authors:  Lucinda Brown; Jinhua Xu-Bayford; Zoe Allwood; Mary Slatter; Andrew Cant; E Graham Davies; Paul Veys; Andrew R Gennery; H Bobby Gaspar
Journal:  Blood       Date:  2011-01-27       Impact factor: 22.113

2.  How I treat severe combined immunodeficiency.

Authors:  H Bobby Gaspar; Waseem Qasim; E Graham Davies; Kanchan Rao; Persis J Amrolia; Paul Veys
Journal:  Blood       Date:  2013-10-10       Impact factor: 22.113

3.  Use of stored dried blood spots for retrospective diagnosis of congenital CMV.

Authors:  Claire Atkinson; Simone Walter; Mike Sharland; Pat Tookey; Suzanne Luck; Catherine Peckham; Paul Griffiths
Journal:  J Med Virol       Date:  2009-08       Impact factor: 2.327

4.  Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening.

Authors:  Morna J Dorsey; Christopher C Dvorak; Morton J Cowan; Jennifer M Puck
Journal:  J Allergy Clin Immunol       Date:  2017-03       Impact factor: 10.793

5.  Neurologic event-free survival demonstrates a benefit for SCID patients diagnosed by newborn screening.

Authors:  Christopher C Dvorak; Jennifer M Puck; Justin T Wahlstrom; Morna Dorsey; Alexis Melton; Morton J Cowan
Journal:  Blood Adv       Date:  2017-09-05

6.  SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.

Authors:  Elie Haddad; Brent R Logan; Linda M Griffith; Rebecca H Buckley; Roberta E Parrott; Susan E Prockop; Trudy N Small; Jessica Chaisson; Christopher C Dvorak; Megan Murnane; Neena Kapoor; Hisham Abdel-Azim; Imelda C Hanson; Caridad Martinez; Jack J H Bleesing; Sharat Chandra; Angela R Smith; Matthew E Cavanaugh; Soma Jyonouchi; Kathleen E Sullivan; Lauri Burroughs; Suzanne Skoda-Smith; Ann E Haight; Audrey G Tumlin; Troy C Quigg; Candace Taylor; Blachy J Dávila Saldaña; Michael D Keller; Christine M Seroogy; Kenneth B Desantes; Aleksandra Petrovic; Jennifer W Leiding; David C Shyr; Hélène Decaluwe; Pierre Teira; Alfred P Gillio; Alan P Knutsen; Theodore B Moore; Morris Kletzel; John A Craddock; Victor Aquino; Jeffrey H Davis; Lolie C Yu; Geoffrey D E Cuvelier; Jeffrey J Bednarski; Frederick D Goldman; Elizabeth M Kang; Evan Shereck; Matthew H Porteus; James A Connelly; Thomas A Fleisher; Harry L Malech; William T Shearer; Paul Szabolcs; Monica S Thakar; Mark T Vander Lugt; Jennifer Heimall; Ziyan Yin; Michael A Pulsipher; Sung-Yun Pai; Donald B Kohn; Jennifer M Puck; Morton J Cowan; Richard J O'Reilly; Luigi D Notarangelo
Journal:  Blood       Date:  2018-08-28       Impact factor: 22.113

7.  Survey of Infection Control Precautions for Patients with Severe Combined Immune Deficiency.

Authors:  Brieanne A Dergousoff; Joseph V Vayalumkal; Nicola A M Wright
Journal:  J Clin Immunol       Date:  2019-08-20       Impact factor: 8.317

8.  Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.

Authors:  Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Jennifer M Puck; Rebecca H Buckley; Fabio Candotti; Mary Ellen Conley; Thomas A Fleisher; H Bobby Gaspar; Donald B Kohn; Hans D Ochs; Richard J O'Reilly; J Douglas Rizzo; Chaim M Roifman; Trudy N Small; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

9.  Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs.

Authors:  Linda M Griffith; Morton J Cowan; Donald B Kohn; Luigi D Notarangelo; Jennifer M Puck; Kirk R Schultz; Rebecca H Buckley; Mary Eapen; Naynesh R Kamani; Richard J O'Reilly; Robertson Parkman; Chaim M Roifman; Kathleen E Sullivan; Alexandra H Filipovich; Thomas A Fleisher; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2008-11-06       Impact factor: 10.793

10.  The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901.

Authors:  Christopher C Dvorak; Morton J Cowan; Brent R Logan; Luigi D Notarangelo; Linda M Griffith; Jennifer M Puck; Donald B Kohn; William T Shearer; Richard J O'Reilly; Thomas A Fleisher; Sung-Yun Pai; I Celine Hanson; Michael A Pulsipher; Ramsay Fuleihan; Alexandra Filipovich; Frederick Goldman; Neena Kapoor; Trudy Small; Angela Smith; Ka-Wah Chan; Geoff Cuvelier; Jennifer Heimall; Alan Knutsen; Brett Loechelt; Theodore Moore; Rebecca H Buckley
Journal:  J Clin Immunol       Date:  2013-07-02       Impact factor: 8.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.